Local Tech Wire
RALEIGH, N.C. – Salix Pharmaceuticals (Nasdaq: SLXP) is raising $300 million through a debt offering, one third higher than originally announced.
The company had said it planned to raise $200 million but reported later Thursday that it had struck an agreement for $300 million in five-year notes.
Salix, which focuses on gastrointestinal products, also reported that the conversion price for the notes to Salix stock is $46.38 per share – a 30 percent premium from its closing price Thursday of $35.68.
Another $45 million was set aside for the underwriters of the offering.
The interest on the notes is 2.75 percent.
Salix said it would net $290 million through the sale. Proceeds will be used for clinical trials, research and development, and commercialization of products.
Bank of America Merrill Lynch and Jefferies & Company handled the offering.
For the full statement about the transaction,
Get the latest news alerts: at Twitter.
